Advances in the regulatory mechanisms of mTOR in necroptosis

Front Immunol. 2023 Dec 18:14:1297408. doi: 10.3389/fimmu.2023.1297408. eCollection 2023.

Abstract

The mammalian target of rapamycin (mTOR), an evolutionarily highly conserved serine/threonine protein kinase, plays a prominent role in controlling gene expression, metabolism, and cell death. Programmed cell death (PCD) is indispensable for maintaining homeostasis by removing senescent, defective, or malignant cells. Necroptosis, a type of PCD, relies on the interplay between receptor-interacting serine-threonine kinases (RIPKs) and the membrane perforation by mixed lineage kinase domain-like protein (MLKL), which is distinguished from apoptosis. With the development of necroptosis-regulating mechanisms, the importance of mTOR in the complex network of intersecting signaling pathways that govern the process has become more evident. mTOR is directly responsible for the regulation of RIPKs. Autophagy is an indirect mechanism by which mTOR regulates the removal and interaction of RIPKs. Another necroptosis trigger is reactive oxygen species (ROS) produced by oxidative stress; mTOR regulates necroptosis by exploiting ROS. Considering the intricacy of the signal network, it is reasonable to assume that mTOR exerts a bifacial effect on necroptosis. However, additional research is necessary to elucidate the underlying mechanisms. In this review, we summarized the mechanisms underlying mTOR activation and necroptosis and highlighted the signaling pathway through which mTOR regulates necroptosis. The development of therapeutic targets for various diseases has been greatly advanced by the expanding knowledge of how mTOR regulates necroptosis.

Keywords: RIPK; ROS; autophagy; mTOR; necroptosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / physiology
  • Mammals / metabolism
  • Necroptosis* / physiology
  • Protein Serine-Threonine Kinases / metabolism
  • Reactive Oxygen Species / metabolism
  • Receptor-Interacting Protein Serine-Threonine Kinases* / genetics
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Reactive Oxygen Species
  • Receptor-Interacting Protein Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases
  • Protein Serine-Threonine Kinases

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The work was supported by National High Level Hospital Clinical Research Funding (No. 2022-PUMCH-B-126), National Key R&D Program of China 2022YFC2009803 from Ministry of Science and Technology of the People’s Republic of China, National Natural Science Foundation of China (No. 82072226), CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-062 from Chinese Academy of Medical Sciences, and Beijing Municipal Science and Technology Commission (No. Z201100005520049).